michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes I probably can get that data. I don't have it at my fingertips and I don't know if anybody from the medical office on the call wants to shoot me a text I'll come back to you. I don't know that right now but we can easily get that number. It's just not my fingertips Michael.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, we can hear you, Heiko. Thank you.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thank you for taking my question. This one's for Tobi or Harley. Just over the past months, the company has introduced search and Shop app, conversion of ads in the partner app store.
And we've seen theoretical headlines like an audience network out there. How are you thinking about advertising as a product category? And what areas do you think makes sense for Shopify to potentially monetize on those products?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Thanks, Alex. Great question, because we know that JAK Inhibitors have a known pharmacology profile. I think what we've been seeing and what we reported in the JAK conference recently is that the key parameters that we continue to monitor in the hematology side of things neutrophils, platelets, etc., are all very stable as we look at longer term dosing. I think this is a very important finding to be reported, but also for us to be continuing to look at, because I believe we have the longest term data out there for JAK Inhibitor coming from controlled trial.
So I think the fact that we're seeing stability of our hematology responses as we now go out in subjects over a year of, you know, continuous dosing is very good sign for this product. And I think it's going to be very important in our submission package as we have all these long-term studies -- this long-term data that we'll be able to put in there. So I think the profile, we're seeing is not inconsistent with what was expected for JAK inhibition. But I think the important thing is that the data shows that we have good stability of these parameters as we continue to dose for a long period of time.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you and good morning everyone. Tony, I would love to get your thoughts on just sort of -- as we think about the next few years or three to five years or how ever you want to frame it, we're in a precarious situation now with obviously very tight grain stocks. And now we've had this spike in gas and coal prices and so forth. And we're having a lot of food inflation. And Bert laid out a very plausible scenario where we could have lower yields because of the inability of everybody to get nitrogen and so forth.
So what do you think the global response to this is going to be over time in terms of trying to manage the food supply and make sure that we kind of don't get into extreme situations like this into perpetuity? But at the same time, we need to balance our sort of climate goals and our green energy aspirations and so forth. So how does this needle get thread in your view?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Right.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, Steve. Let me let John Engquist respond to that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I'm just going to be careful. If we're up about 8% is the question, I don't know that it will be. But I think our view is by the middle of next year with sort of the full ramp of our cost restructuring initiatives, we're going to be in a really good place. We do expect to be at or below pre-COVID CASMex.
Ultimately, we've said that from the very beginning. I don't know if we would hit it by next summer, but we should be there or getting very close to there. But I don't think I'll be more specific than that. It's -- I think we're going to have a really good cost structure.
One thing we know we're going to not do is lose sort of relative advantage to others in the industry. So we're super focused on this cost discipline and execution. The productivity stuff that we're seeing right now makes us very -- makes us feel very good about how we've executed to date.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
That's right. We would expect to better the rents that were in place with the incumbent tenant.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. What I would say is the majority did hit the labor line item.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Good morning, Kevin. I'll give you an example, but I would add to that list of background screening, education also just the baseline and willingness to consider increasing wages is also, obviously, an important important factor. But in the case of the background screening, we recently shared a case study that we had with Toyota in a huge manufacturing facility. We've been working with Toyota to open up the top of their talent funnel by allowing candidates with non-violent, non-relatable criminal convictions to be considered for work at Toyota and 92% of the candidates actually passed the screening requirements that we established with Toyota.
Literally hundreds of people found work there. Toyota increased their talent pool by 20%, the increase of diversity by almost 10% and they lowered their turnover by 70%. And that's the kind of story that we're seeing among other customers that are willing to revisit these many policies, whether it's education or background screening that have been in place for decades and rarely revisited. And our Kelly 33 program is particularly targeted at the criminal conviction background. But we have other programs that we're undertaking with customers, who are frankly starved for talent and are willing to relook at their approach.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So, we've been building backlog throughout the year and it did grow quite healthy in Q3 as well as you noted, Rod. It is really across the board. I mean, backlog is up across all customer solutions. I would say that the automotive WAN is up a little bit more than the others, but it really is an across-the-board backlog build with a little bit more slanted toward automated WAN. So, we are entering the fourth quarter, and I believe next year with a very healthy backlog across all products, but automated when it is, I would say, the healthiest, if you will.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
[Speech Overlap] Sorry about it. That's about 4%.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, no. So they -- first of all, this was a non-invasive. So this was a -- was not a biopsy trial. So we didn't look at fibrosis in this particular trial. We also did not repeat, like for example of a fibroscan measurement. The MRI data is really the only thing that we have. Seeing a change in fibrosis within four weeks, which was the treatment duration for most of these patients would be absolutely unexpected but we wouldn't know, we didn't know.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good evening, everyone. Thanks for taking my question. I appreciate the color so far on guidance. Just wanted to go back on some of the comments you made around the capex coming from rationalization while keeping the cash flow NPV neutral.
Are you able to comment where you made the capex reductions in that particular regard? And whether this could limit Plains' operating leverage if we see stronger recovery end growth than you are anticipating?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'm going to say the majority is going to be from new usage at existing and adding in new clients because our larger contracts are coming up for renewal now. The two main ones with No. 4 and No. 3 are now and at the end of the year.
I'd say that a small, but significant portion, I guess, as a percentage of what it was in the age-restricted space, but it's still a small portion of the revenues. So I'm going to say that most of it, a good chunk of it are the firms that we have brought on over the course of the pandemic that weren't really producing at the level of the normal world. And then the rest is going to be new clients. But off the top of my head, I don't have the specific breakdown of that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
OK. So I'll separate the two questions. The booster studies again, we are still preparing the protocols. Typically you have to wait for any boosters for the required.
In the COVAXIN case, we're doing the booster after 28 days after the first dose. Similarly, if -- you want to space them out. For other vaccinees, at least a month or more, and that could be determined. Our clinical teams are headed by Dr.
Bruce Forrest, an expert in this field, and over again to make those additions in the upcoming months before we file the protocol with the FDA. And the second part is are you going to monitor long-term durability? I think our partners have already published extensive data. I think in the Lancet and others and they're continuing to monitor the long-term durability of this vaccine. And typically what is important is I think the missing piece people have to understand it's not just the safety and efficacy.
Efficacy is a at one time if you're measuring as a part of the Phase III clinical trial and it's really important to measure the responses -- similar responses and decent responses. And that's where you're going to get the durability on.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Steven.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So I'm glad you asked actually. So same-store, we were down 11.8% first quarter 2021 over first quarter 2020. A big part of that was very, very heavy data center, like hundreds and hundreds and hundreds of people on some data center job in the fourth and first quarter of last year. So, although we will face same-store revenue headwind in the second quarter, we'll not be at near the left -- if it was -- let's say, it was 12% in the first quarter, we'll be low- to mid-single-digit, most likely best guess in the second quarter. And then, for the rest of the year we think we have manageable revenue comparables. Having said that, I would say, work is starting and that can -- a month delay that -- it is -- one of the reasons we are positive about 2022, which is not like us this early in the year, because we have so much work starting in the second half of this year, but of course, it has to go into 2022. But there is -- like some of that timing could matter a little bit, right? So, having said that, it is -- they're fair comparables in the second half of the year. I have hard time telling you, we'd be up much, but we shouldn't be down.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. We've had -- we have a lot of traction with other Chinese customers of ours outside of Huawei. I think it's going to take a considerable time given the size differences between Huawei in China and the rest of China suppliers in China.
Now, our expectations is that those other companies continue to grow and our traction with them is very strong. So I don't know if it's quarters or years, but I think from that perspective, we do have higher share of wallet I would say outside of Huawei with other Chinese customers as well as Western customers. And so, if or when share moves from a Huawei network to another supplier network, we believe that's a tailwind for us.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
That would be all-in. The caveat around operating basis is it's exclusive of the MSR mark to market, so it'd be including everything but the MSR mark to market.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Thanks, Michael. John here. Certainly we have seen some costs increase.
A lot of those commodities are levelizing a bit, or some of them are, but we've seen that at least to our estimates, so we do see some additional costs for the solar going forward. The projects we have that we've filed for with our first CA in Wisconsin, and we expect others are very low cost. So they're very, very competitive costs even with these increases, and of course, they provide significant benefits for our customers over time. So well-positioned, a lot of flexibility in our plan, but we have seen some increases on commodities, as I'm sure most of our peers have as well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So again, I'll let Jonathan answer the question about details into background therapy and so on. On your first point, Joe, in terms of teasing out additional information, we obviously continue to look at individual patient data exactly as you're suggesting and we'll always look to see if there are learnings, but I think fundamentally it's too small a number of patients to lead to any shift in terms of thinking. We do absolutely look at the individual patient data and see if there are directional things that one might interpret, it's something we talk about a lot. But there's nothing given the small size of the study that we see as you're changing anything we thought of before.
And then, Jonathan, do you want to talk about background therapy that we're anticipating in the phase two in atopic dermatitis?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So I would say, Alex, as we look at our business, we have a good lineup. We have scale. We have a global platform today. It's not as though, however, I could say we have everything we would want in fixed or equities or solutions in all parts of the world. So I think we individually evaluate that from sort of the core of what we do manage today as well as looking at more of the type of platforms that are necessary. So we're growing a bit more in our solutions business. We're adding some alternatives, some real estate and things like that over time.
So it's more of, are their other distribution capabilities and other methods to add to. And how we manage assets for clients, things like that as well as from a product perspective. We're not against adding scale. Let me be very clear about that. But it would have to be a transaction where it gives us a complement of things rather than we just want to put assets on the platform.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So that's a complicated question because of the nature of some of these contracts by customer type, by region. But let me just kind of state -- restate what we talked about the last two quarters that, a, you could expect quarter -- quarter-over-quarter improvement in this business, steady improvement in this business and we're seeing that. But our strategy is to have the kind of margins in this business that reflect the value that fluff pulp provides for the end-use customers. So we're taking a very structured, very measured approach to each market segment and to the agreements we currently have in those segments with individual customers.
And so as we implement this approach, we would expect that there'll be some volume shifts and movement between segments. And our goal is to have mix improvement, better agreements with better economics that reflect the value of fluff pulp. And that is a kind of customer-by-customer, region of the world by region of the world.
And I would expect, and we're making progress, good progress on that, that given the length of some of these agreements and the way they're structured, we should expect to continue to see margins improve over the next several quarters. So that's a long, complicated answer to would we have any more price flow-through. It's not just about price flow-through, it's about restructuring these commercial agreements and getting the proper value for this product.

    Prediction (one of UP, DOWN, SAME): SAME